Table 1 Baseline characteristics of patients treated with amikacin
Baseline characteristics | N = 107 (%) |
|---|---|
Sex, Female | 70 (65.4) |
Age (Years), Mean (SD) | 58.3 (14.9) |
Race | |
 Caucasian | 72 (67.3) |
 South Asian | 4 (3.7) |
 East Asian | 28 (26.2) |
 African | 3 (2.8) |
Comorbidities | |
 COPD/Emphysema | 19 (17.7) |
 Previous TB | 13 (12.1) |
 Cystic fibrosis | 6 (5.6) |
 Asthma | 5 (4.7) |
 Autoimmune disorders | 5 (4.7) |
 Alpha 1 antitrypsin deficiency | 2 (1.9) |
 Sarcoidosis | 2 (1.9) |
 ABPA | 2 (1.9) |
 Allogenic stem cell transplant | 2 (1.9) |
 HIV infection | 1 (0.9) |
Species | |
 MACa | 69 (64.5) |
 M. abscessus | 21 (19.6) |
 M. xenopi | 11 (10.3) |
 MAC and M. xenopi | 4 (3.7) |
 M. shimodei | 1 (0.9) |
 M. fortuitum | 1 (0.9) |
AFB smear positive ever | 100 (93.5) |
Aspergillus isolation | 39 (36.4) |
CT pattern | |
 Nodular bronchiectatic | 55 (51.4) |
 Fibrocavitary | 40 (37.4) |
 Random nodules | 2 (1.9) |
 Consolidation | 0 (0) |
 Unclassifiable | 10 (9.3) |
Cavity | 66 (61.7) |
Indication for treatment | |
 First line | 39 (36.4) |
 Second line | 68 (63.6) |